Haemonetics Corporation Common Stock (HAE)
Healthcare › Surgical & Medical Instruments & Apparatus
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- Trading 99% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 7/9 — financially strong with improving fundamentals
- ROE of 19.5% — good return on equity
Haemonetics Corporation Common Stock (HAE) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NYSE , with a market capitalisation of $3.3 billion . Key value metrics: P/E ratio 21.3, P/B ratio 4.15, Piotroski F-Score 7 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Haemonetics Corporation Common Stock — Fundamental Analysis Summary
Haemonetics Corporation Common Stock (HAE) is currently trading 99% above its Graham Number of $36.66, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 21.3x.
On financial health, HAE shows a strong Piotroski F-Score of 7/9, indicating improving fundamentals across profitability, leverage, and efficiency, and solid return on equity of 19.5% (sector average: -20.6%), and elevated leverage with a debt-to-equity ratio of 1.56.
StockPik's composite Value Score for HAE is 74/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
HAE reports a solid gross margin of 58.6% (sector average: 39.4%) and a solid operating margin of 17.9%.
HAE shows revenue declining at 2% year-over-year, with earnings declining at 42%.